Pyxis Oncology, Inc. (PYXS) Stock Price & Analysis
Pyxis Oncology, Inc. (PYXS) rose 9.12% to USD 3.89 as of September 8, 2026 at 03:29 UTC, according to Nexqual real-time market data.
PYXS last closed at USD 3.57; the session ranged USD 3.53–4.05 on volume of 2,230,891 shares. Market capitalization is $324.46M, with a 52-week range of USD 1.03–5.55 (NMS). Source: Nexqual, September 8, 2026 at 03:29 UTC.
Key Statistics (as of September 8, 2026 at 03:29 UTC)
| Price | USD 3.89 |
|---|---|
| Change | ▲ 9.12% (up) |
| Previous Close | USD 3.57 |
| Open | USD 3.53 |
| Day Range | USD 3.53 – 4.05 |
| 52-Week Range | USD 1.03 – 5.55 |
| Volume | 2,230,891 shares |
| Market Cap | $324.46M |
| Exchange | NMS |
Technical Analysis (PYXS)
Nexqual's technical model rates PYXS "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 03:29 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 66.76 (neutral) |
| vs SMA50 | Above (USD 2.96) |
| MACD | 0.2 (positive) |
Analyst Ratings (PYXS)
Wall Street analysts rate PYXS "None" based on 9 analysts, with a mean price target of USD 7.22 (range USD 5–12), per Nexqual as of September 8, 2026 at 03:29 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 7.22 |
| High Target | USD 12 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (PYXS)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD -0.28 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.4 vs est -0.35 ▼ miss |
| 2026-03-31 | USD -0.37 vs est -0.35 ▼ miss |
| 2025-12-31 | USD -0.29 vs est -0.34 ▲ beat |
| 2025-09-30 | USD -0.35 vs est -0.34 ▼ miss |
Source: Nexqual, September 8, 2026 at 03:29 UTC.
Financials & Fundamentals (PYXS)
| Total Revenue | $11.04M |
|---|---|
| Gross Margin | +78.37% |
| Operating Margin | -812.74% |
| Profit Margin | +0.00% |
| ROE | -179.10% |
| Debt / Equity | 155.87 |
| Current Ratio | 1.34 |
| Total Cash | $33.00M |
| Total Debt | $17.83M |
| Free Cash Flow | $-23.19M |
Source: Nexqual, September 8, 2026 at 03:29 UTC.
Financial Health Score (PYXS)
Nexqual rates Pyxis Oncology, Inc.'s overall financial health "Critical" across five dimensions, as of September 8, 2026 at 03:29 UTC.
| Growth | Critical — Revenue -14% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $33M cash vs $18M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$23M, burning cash |
| Efficiency | Critical — ROE -179%, ROA -63.0% |
Ownership (PYXS)
| Insider Ownership | +13.53% |
|---|---|
| Institutional Ownership | +42.50% |
| Shares Outstanding | 83.41M |
| Float | 49.56M |
| Short % of Float | +6.62% |
Source: Nexqual, September 8, 2026 at 03:29 UTC.
Leadership (PYXS)
Pyxis Oncology, Inc. is led by Thomas Civik (age 56), Interim CEO & Director, per Nexqual as of September 8, 2026 at 03:29 UTC.
| Interim CEO & Director | Thomas Civik (age 56) |
|---|---|
| Interim Chief Technology Officer | Balu N. Balasubramanian |
| Senior Vice President of Portfolio & Program Management | Charles T. Gombar |
| Senior Vice President of Global Regulatory Affairs | Michael Bui |
Major Backers & Investors (PYXS)
Notable institutional backers of Pyxis Oncology, Inc. include GordonMD Global Investments LP, Pfizer Inc, Laurion Capital Management, LP, according to Nexqual as of September 8, 2026 at 03:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| GordonMD Global Investments LP | 12.02% |
| Pfizer Inc | 8.43% |
| Laurion Capital Management, LP | 5.88% |
| Atle Fund Management AB | 1.16% |
| Palo Alto Investors Lp | 1.04% |
| Marshall Wace LLP | 1% |
| Renaissance Technologies | 0.93% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.93% |
| BlackRock | 1.69% |
| Geode Capital | 0.71% |
Source: Nexqual, September 8, 2026 at 03:29 UTC.
From Pyxis Oncology, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe various potential alliance structures including collaborations, licenses and future agreements could potentially provide significant funding to advance our pipeline and could allow us to benefit from the additional resources, development and commercialization expertise of our collaborators. • Maximize value from our intellectual property and technology platforms.
Partnerships
- MICVO Combination Therapy In November 2024, we announced a Clinical Trial Collaboration and Supply Agreement with Merck & Co, Inc. or Merck (known as MSD outside of the United States and Canada), for a Pyxis Oncology-sponsored study of MICVO in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
- PYX-201-102 Combination Therapy Phase 1/2 Trial In November 2024, we entered into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc. ("Merck") (known as MSD outside of the United States and Canada), pursuant to which we are conducting a Pyxis Oncology-sponsored clinical study evaluating MICVO in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TCRX | TScan Therapeutics, Inc. | USD 0.39 | ▲ 2.76% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.97 | ▼ 3.18% |
| XLO | Xilio Therapeutics, Inc. | USD 9 | ▲ 1.81% |
| ABOS | Acumen Pharmaceuticals, Inc. | USD 3.18 | ▲ 2.58% |
| BMEA | Biomea Fusion, Inc. | USD 2.03 | ▲ 4.91% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 03:29 UTC. This page is informational and not investment advice.